GSK avoids $57m damages award over royalties

GlaxoSmithKline (GSK) has avoided paying $57 million in damages after a US court reversed a ruling that the pharmaceutical company should not have stopped issuing royalties on a lupus drug.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

GSK responds to Teva’s ‘skinny’ label rehearing petition

9 December 2021 Following a substantial push from generics companies to reverse the GSK v Teva “skinny” label ruling, GlaxoSmithKilne has added its response to the petition to rehear the case yet again.

Americas

Fed Circ panel reviews $235m GSK award over ‘skinny’ Teva generic

25 February 2021 A panel of the US Court of Appeals for the Federal Circuit has considered for a second time the $235 million award to GlaxoSmithKline after Teva Pharmaceuticals was found to have infringed its Coreg heart drug.

Big Pharma

Court denies Lilly’s application to block GSK SPC

23 July 2014 The English High Court has dismissed an application by Eli Lilly to stop Human Genome Sciences from getting an SPC based on a marketing authorisation Lilly may receive for a new drug.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

GSK avoids $57m damages award over royalties

More on this story

Editor's picks

Editor's picks

More features